98%
921
2 minutes
20
Background: Machine learning (ML) has been successfully implemented for classification tasks (e.g., cancer diagnosis). ML performance for more challenging predictions is largely unexplored. This study's objective was to compare machine learning vs. expert-informed predictions for surgical outcome in patients undergoing major liver surgery.
Methods: Single tertiary center data on preoperative parameters and postoperative complications for elective hepatic surgery patients were included (2008-2021). Expert-informed prediction models were established on 14 parameters identified by two expert liver surgeons to impact on postoperative outcome. ML models used all available preoperative patient variables (n = 62). Model performance was compared for predicting 3-month postoperative overall morbidity. Temporal validation and additional analysis in major liver resection patients were conducted.
Results: 889 patients included. Expert-informed models showed low average bias (2-5 CCI points) with high over/underprediction. ML models performed similarly: average prediction 5-10 points higher than observed CCI values with high variability (95% CI -30 to 50). No performance improvement for major liver surgery patients.
Conclusion: No clinical relevance in the application of ML for predicting postoperative overall morbidity was found. Despite being a novel hype, ML has the potential for application in clinical practice. However, at this stage it does not replace established approaches of prediction modelling.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.hpb.2024.02.006 | DOI Listing |
Surg Endosc
September 2025
Department of Surgery, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands.
Background: The implementation of minimally invasive liver surgery (MILS) for perihilar (PHC) and intrahepatic cholangiocarcinoma (IHC) remains limited and a systematic review including only comparative studies of MILS versus the open approach is lacking. This systematic review and meta-analysis aimed to assess the safety and efficacy of minimally invasive surgery in patients with hilar and intrahepatic cholangiocarcinomas.
Methods: Systematic review in the PubMed, Embase, and Cochrane databases for original studies comparing at least five patients undergoing MILS with open liver surgery for PHC and IHC.
Rev Gastroenterol Mex (Engl Ed)
September 2025
Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia; Departamento de Medicina Interna, Servicio de Gastroenterología, Fundación Valle del Lili, Cali, Colombia. Electronic address:
Introduction And Aim: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare neoplasms originating in neuroendocrine cells from the gastric mucosa and submucosa, small intestine, large intestine, rectum, and pancreas. Our aim was to describe their histopathologic, endoscopic, and clinical characteristics and the experience with these tumors at a tertiary care hospital center in the Colombian Southwest.
Materials And Methods: A retrospective, analytic, observational, and descriptive study included 93 patients diagnosed with GEP-NETs, within the time frame of 2018 and 2022.
Trends Mol Med
September 2025
Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address:
Ferroptosis, a regulated cell death pathway driven by iron-catalyzed lipid peroxidation, has recently been implicated as a major cause of hepatic injury in metabolic dysfunction-associated fatty liver disease (MAFLD). This review highlights how the identification of hyperoxidized peroxiredoxin 3 (PRDX3) as a ferroptosis-specific marker has led to the discovery that ferroptosis contributes to liver injury in MAFLD, and summarizes other emerging evidence connecting ferroptosis to MAFLD pathogenesis. These new findings suggest that dietary fat composition and genetic variants such as PNPLA3(I148M) may affect the progression of MAFLD by regulating cellular sensitivity to ferroptosis.
View Article and Find Full Text PDFJ Am Coll Cardiol
September 2025
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region of China; Advanced Data Analytics for Medical Science Limited, Hong Kong Special Administrative Region of China
Background: There is no consensus for using statins for primary prevention of cardiovascular disease (CVD) and all-cause mortality in adults with type 1 diabetes mellitus (T1DM), because no randomized controlled trial has exclusively investigated statins in this population.
Objectives: In this study, the authors sought to evaluate the long-term risks and benefits of statins for primary prevention in adults with T1DM.
Methods: We performed a sequential target trial emulation comparing statin initiation vs noninitiation using UK primary care data from the IQVIA Medical Research Data database.
BMJ Open
September 2025
Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxication, University Hospital Heidelberg, Heidelberg, Germany.
Introduction: Combined vascular endothelial growth factor/programmed death-ligand 1 blockade through atezolizumab/bevacizumab (A/B) is the current standard of care in advanced hepatocellular carcinoma (HCC). A/B substantially improved objective response rates compared with tyrosine kinase inhibitor sorafenib; however, a majority of patients will still not respond to A/B. Strong scientific rationale and emerging clinical data suggest that faecal microbiota transfer (FMT) may improve antitumour immune response on PD-(L)1 blockade.
View Article and Find Full Text PDF